Gapping up
In reaction to strong earnings/guidance:
- APRN +12.5%, PLAY +6.8%, RBBN +4.7%, MUX +2.2%, TTMI +1.8%, CPG +1.5%, CHEF +0.8%
Other news:
- ARRY +9.8% (announces updated safety and efficacy results from Phase 3 BEACONC CRC trial)
- TRXC +9.4% (confirms receipt of FDA 510(k) clearance for its Senhance Ultrasonic System)
- NBEV +8.3% (ongoing volatility)
- BGNE +4% (receives FDA Breakthrough Therapy designation of zanubrutinib for the treatment of adult patients with mantle cell lymphoma)
- EXEL +3.9% (announces FDA approval of CABOMETYX tablets for previously treated hepatocellular carcinoma)
- GNW +3.3% (Genworth Financial receives approval from New York regulator for proposed Oceanwide transaction)
- TLRY +3.1% (Tilray and Authentic Brands Group sign global revenue sharing agreement to develop and market consumer cannabis brands)
- FFBC +1.1% (announces stock repurchase plan of up to 5.0 mln shares of common stock)
- BABA +0.8% (after seeing late sell-off as exec comments from conference circulated)
- MU +0.8% (Micron exercises right to purchase Intel's (INTC) interest in the IM Flash Technologies joint venture for approx. $1.5 bln, as previously disclosed)
Analyst comments:
- BOX +3.4% (upgraded to Buy from Neutral at Rosenblatt)
- INCY +3% (added to Conviction Buy List at Goldman)
- HP +0.5% (upgraded to Overweight from Neutral at JP Morgan)
